Pharma & Biotech News– category –
-
UK Series (Part 1): The UK Life Sciences Strategy: Policy, Regulation, and Investment at Full Tilt
Executive Summary｜The UK’s 2025 industrial strategy update places life sciences among its priority sectors, aiming to become Europe’s No.1 by 2030 and the world’s No.3 by 2035. In lockstep with the NHS long-term roadmap, the plan combin... -
Bonus Track Special: Implications for Japan & Asia — How US “Reallocation” Reshapes Opportunities
Category: Pharma & Biotech NEWS | Special Feature B Key Takeaways Capital follows the cleared path (POC → CMC → access): US selectivity raises the bar for Asia-origin programs on speed, manufacturability, and reimbursement narrative.... -
Bonus Track-Special: Redesigning M&A & Partnerships — From Overlap Removal to “Rights Architecture”
Category: Pharma & Biotech NEWS | Special Feature A Key Takeaways PMI defines value: 80% of deal value crystallizes within 90–180 days post-close through speed and transparency; eliminate overlaps with KPI governance. Rights redesign... -
Series “Reading 2025 Layoffs” — Final: Practical Playbook: Checklists and Capital Strategy for Founders & Investors (Part 5)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 5 (Final) Key Takeaways Event-synced planning: script data (BM → topline) and financing (FPO/debt/partnerships) to minimize dilution. Shortest path to POC: focus ... -
Series “Reading 2025 Layoffs”: The Funding Climate: How Selectivity Works Across VC, Public, Debt, and M&A (Part 4)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 4 Key Takeaways Capital concentrates near POC: late-stage/near-commercial assets attract flows; discovery–preclinical is tightly screened; non-dilutive capital br... -
Series “Reading 2025 Layoffs”: Modality-by-Modality: Manufacturing, Regulatory, and Commercial Realities (Part 3)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 3 Key Takeaways The “capital-efficiency equation” is modality-specific: even with similar P2 wins, cell/gene/RNA/antibody–degrader programs require very different... -
Series “Reading 2025 Layoffs”: Reshaping by Disease Areas: From Oncology to Neuroscience (Part 2)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 2 Key Takeaways Oncology leads the reallocation: Cell therapies and solid tumors force a focus on indication picking, manufacturability, and reimbursement realism... -
Series “Reading 2025 Layoffs”: 2025 Biotech/Pharma Layoffs at a Glance: What Happened and Where It Concentrated (Part 1)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 1 Key Takeaways Selectivity & Focus: Layoffs reflect a disciplined reallocation—shifting resources toward late-stage/validated assets while compressing broad ... -
China Biopharma Deals, 2019–2025: Part 4 — Regulatory History, Why It Surged, Adoption Checklist, and Outlook
This final part pulls together the structural drivers — regulation, capital formation, clinical infrastructure — and turns them into a practical adoption checklist. We close with our own view of what comes next and where value will accru... -
China Biopharma Deals, 2019–2025: Part 3 — Respiratory/Immunology, CNS, Infectious and More
Beyond oncology and metabolic, partnering has matured in respiratory and immunology, CNS, and infectious diseases. This article explains why “bundled” multi-program options help both sides, how regional split deepens, and what operationa... -
China Biopharma Deals, 2019–2025: Part 2 — Obesity and Metabolic (Oral GLP-1, Dual Agonists)
Obesity and type 2 diabetes are massive in clinical burden and market size. China-origin programs are notable in oral GLP-1 design and in practical, scalable manufacturing plans. This article guide beginners through outcomes interpretati... -
China Biopharma Deals, 2019–2025: Part 1 — Oncology (ADC, Bispecifics, IO, Cell Therapy)
Oncology is the tip of the spear for China-origin innovation in global partnering. This article gives you a bird’s-eye view of the major deals, then goes deep into the operating logic behind ADCs, bispecific antibodies, checkpoint inhibi... -
Obesity Drug Updates Part 2: Pricing and Reimbursement of GLP-1 Obesity Drugs Across Japan, the U.S., and Europe
Introduction: Innovation Means Nothing Without Access GLP-1 obesity drugs have created explosive demand worldwide, but the critical bottleneck is cost. With prices reaching hundreds of dollars per month and long-term treatment required, ... -
Obesity Drug Updates Part 1: Novo’s Layoff and the Next Phase of GLP-1 Obesity Drugs – Innovation and Pipeline Competition
Introduction: Novo’s Layoff as a Symbol of Industry Transition In September 2025, Novo Nordisk announced a massive layoff of about 9,000 employees, roughly 12% of its global workforce. The decision comes amid intensified competition in t... -
[August 2025 Update] The Frontline of the Obesity Drug Race: Lilly’s Setback, Emerging Biotechs, Big Pharma Strategies, and Chugai’s Moves
Introduction As of August 2025, the obesity drug race is undergoing major shifts. Eli Lilly and Novo Nordisk remain dominant, but biotech challengers and Big Pharma entries are redrawing the competitive map. This article reviews the late... -
Why Gene & Cell Therapies Stall at the FDA (2024–2025): What Recent CRLs Reveal about CMC, Inspections, and Trial Design
In July 2025, the FDA began publishing past Complete Response Letters (CRLs). Triangulating those releases with company disclosures and primary reporting shows two dominant themes: CMC (quality/manufacturing/testing) & Pre-License In... -
Pharma/Biotech News | Layoff Trends in the U.S. Biotech Sector 2025: Industry Reset or Prelude to a New Wave?
Fierce Biotech's "Layoff Tracker 2025" has captured a wave of downsizing across the U.S. biotech landscape in the first half of 2025. This article breaks down key layoffs, underlying causes, industry categories impacted, and what this mi... -
【Biotech Investment News】Sanofi’s Strategic Deals in 2025: A Comprehensive Summary
Key Pharma Moves: Sanofi’s Acquisitions and Collaborations in Q1–Q3 2025 In 2025, Sanofi has executed several key strategic acquisitions and licensing deals focused on immunology, neurology, and rare diseases. Here's a summary of these d... -
[Pharma & Biotech News] Personalized mRNA Cancer Vaccine Development Accelerates: Nature Biotechnology Review
A comprehensive review published in the June 2025 issue of Nature Biotechnology summarizes the current status of personalized mRNA cancer vaccine development. Neoantigen-based mRNA vaccines, tailored to individual patients' tumor mutatio... -
[RWD & Genomics Business Special] 23andMe’s Acquisition Highlights the Challenges and Opportunities in Real-World Data
23andMe, once one of the largest direct-to-consumer (DTC) genomics companies with a vast database of genetic, familial, and self-reported health data, has entered bankruptcy proceedings. While Regeneron was initially seen as a potential ...
